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1. Introduction
Discovery of stem cells by James Till and Ernest McCulloch in 1961, stands as one of the most
remarkable medical-research achievements of the 20th century. This discovery provided a
foundation for further breakthroughs in the field of stem cells. Sir Martin J. Evans along with
Mario R. Capecchi, and Oliver Smithies were jointly awarded a Nobel Prize in 2007 for their
contribution in introducing specific gene modifications in mice by the use of embryonic stem
cells. Later in 2012, John B. Gurdon and Shinya Yamanaka were also jointly awarded a Nobel
Prize for discovering that mature cells can be reprogrammed to become pluripotent cells. [1]
Ramon y Cajal in 1926 stated “Once the development was ended, the founts of growth and
regeneration of the axons and dendrites dried up irrevocably. In the adult centers, the nerve
paths are something fixed, ended, and immutable. Everything may die, nothing may be
regenerated. It is for the science of the future to change, if possible, this harsh decree.” [2]. It
was a long-standing belief that cells of the central nervous system once damaged cannot be
regenerated. The medical science of stem cells has finally made restoration of CNS possible
which has changed the old concept of medicine. Not too long ago, this therapy was hamstrung
by various controversies, ethical and moral issues. But, tremendous progress of research in
this field has finally led to its translation from laboratory to innovative cellular therapies.
A variety of cells including embryonic stem cells, adult stem cells, umbilical cord blood cells
and induced pluripotent stem cells have been explored as a therapeutic alternative for treating
a broad spectrum of neurologic disorders including stroke, Alzheimer’s, Parkinson’s, spinal
cord injury, cerebral palsy etc. amongst others. It is essential to select suitable cells depending
on the nature and status of neurological dysfunctions to achieve optimal therapeutic efficacy.
Along with the selection of cells, the route of administration also plays an important role to
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maximize the clinical therapeutic effect of the cell therapy. Numerous preclinical studies have
been carried out to study the safety of intrathecal, intravenous and direct cerebral implantation.
A plethora of published literature is also available to provide evidence of stem cells initiating
functional restoration of CNS. The postulated mechanisms of action involved are neuromo‐
dulation, neuroprotection, axon sprouting, neural circuit reconstruction, neurogenesis,
neuroregeneration, neurorepair, and neuroreplacement.
In view of the fact that stem cell therapy has a promising therapeutic potential in the treatment
of neurological disorders, it is important for all the professionals in the medical field to
understand the concepts of this upcoming therapeutic strategy.
In this chapter, we have focused on stem cell therapy for Cerebral Palsy (CP) which is a
heterogeneous group of neurological disorders mainly observed in infants. It results due to a
static brain lesion at the time of pregnancy or early life. The survival of CP children has
increased due to advanced modern medicine which has led to their growing population. CP
involves impairment of movement, muscle function, and cognitive functioning and the effects
range from mild to severe. [3] Chronic motor disability along with intellectual disability,
epilepsy, behavioral disorders, and sensory and perceptual disturbances are few of the
complications seen in these patients. No biological intervention has been effective for CP and
the standard approach is limited to supportive management strategies which do not address
the core issue of neural tissue damage. Currently, stem cell based strategies have garnered
attention due to their ability of neuroregeneration and neuroprotection in CP.
We have discussed the clinical aspects of stem cell therapy in cerebral palsy supported by
various human case studies and clinical trials. We have also enumerated our experience and
results wherein our subjects were administered autologous bone marrow mononuclear cells.
In our study it was found to be safe, feasible and efficacious and may be used as a combinatorial
strategy with the currently available standard treatments.
Here, we try to summarize the current vast knowledge available for stem cell therapy in
cerebral palsy.
2. Stem cells
Stem cells are defined as “cells that have the ability to renew them continuously and possess
pluripotent or multipotent ability to differentiate into many cell types.” [4]These cells exhibit
a unique property of “plasticity” where in cells isolated from one tissue convert to cells of
different tissues by crossing lineage barriers and adopting the expression profile and pheno‐
type of cells that are unique to other tissues. [5]
Stem cells are categorized based on their potential to differentiate into other types of cells.
1. Totipotent cells: These cells have the ability to differentiate into all possible cell types of
the human body including extra embryonic and placental cells.
Cerebral Palsy - Challenges for the Future218
2. Pluripotent cells: These cells have ability to differentiate into any of the three germ layers
viz. endoderm, mesoderm and ectoderm.
3. Multipotent cells: These cells have the ability to differentiate into specialized cells.
4. Oligopotent cells: These cells have the ability to differentiate into a few cell types.
5. Unipotent cells: These cells have the ability to produce cells only of their own type, but
are capable of self-renewal to be classified as a stem cell.
2.1. Types of stem cells
Stem cells are broadly classified based on their source, as follows:
i. Embryonic stem cells (ESCs): These cells are pluripotent cells derived from a 4-7 day
old blastocyst stage embryo. The cells are harvested from the inner cell mass (ICM)
of the blastocyst. Invitro, they can be indefinitely maintained and expanded as pure
populations of undifferentiated cells. [6] Inspite of their great potency in tissue repair,
these cells have triggered various ethical and moral issues due to the destruction of
human embryos involved. [7] They also have tumorigenic side effects as ESCs and
tumor cells share cellular and molecular phenotypes such as rapid proliferation rate,
lack of contact inhibition, a susceptibility to genomic instability, high activity of
telomerase, high expression of oncogenes and epigenetic status amongst others. They
form teratomas which have the potential to degenerate into malignant teratocarci‐
nomas [8] The likelihood of development of tumors in children cannot be overlooked
as they have many years of life ahead of them for the tumor formation to occur.
ii. Fetal Stem Cells: These cells are isolated either from the aborted fetus or from the
extra embryonic structures of the fetal origin such as the amniotic fluid and placenta.
Fetal blood is a rich source of haemopoietic stem cells (HSC). Non-haemopoietic
mesenchymal stem cells (MSC) are also found in the first trimester fetal blood. [9]
These cells have better homing capacity, greater multipotentiality and differentiation
potential and lower immunogenicity as compared to the allogeneic adult stem cells.
[10] Although these cells have a greater therapeutic potential they may also be
associated with infections. These cells are prone to KS-associated herpes virus
(KSHV) infections. [11] As the safety is not yet substantiated, fetal cells are not often
used for transplantation. Use of fetal cells is ethically controversial as it is associated
with abortion. Research on fetal cells is permitted only after the decision of abortion
is made.
iii. Umbilical cord: Umbilical cord contains a heterogeneous mixture of stem/ progenitor
cells at different lineage commitment stages. Cells are isolated either from the cord
blood or the Wharton jelly. They consist of embryonic stem cell-like and other
pluripotential stem cells, which can give rise to hematopoietic, epithelial, endothelial,
and neural tissues. [12] Various banks have evolved to collect and preserve the
umbilical cord blood. But the utility of these centers is still questionable. The protocols
and guidelines for collection and retrieval of cells are still being standardized. Other
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disadvantages of use of UCBCs are limited by the fact that minimum necessary
dosage of cells for cell engraftment is 1 × 107 cells per kilogram which includes the
total nucleated cell fraction along with stem cells. Thus, the available dose of autol‐
ogous cells obtained at birth may be insufficient for transplantation at an older age
of the child [13].
Amount of stem cells found in the cord blood is 10% less than that obtained from the bone
marrow. [14] There are some reports of associated Herpes virus and JC virus infection by
allogeneic UCBCs transplantation [15,16]
iv. Induced pluripotent stem cells (iPSC): To circumvent the ethical issues involved in
the use of embryonic stem cells, pluripotent cells were generated directly from the
patients' own cells. Induced pluripotent stem cells are non-pluripotent adult cells
(somatic cells) which have been genetically reprogrammed to form pluripotent cells.
The iPSC technology develops patient-specific cell therapy protocols. The availability
of iPSCs is particularly advantageous for research involving neurological diseases,
since it is difficult to obtain diseased tissue sample for study from living patients. [17]
v. Adult stem cells: These cells are multipotent stem cells, isolated from adult tissues
(i.e. after birth). They include hematopoietic stem cells, bone marrow derived stem
cells, adipose tissue-derived stem cells, neural stem cells amongst others [18] Adult
stem cells are found in almost all the tissues of the body and help to maintain and
repair organs and tissues throughout a person's life. These cells are majorly found in
the bone marrow, brain, skeletal muscle, liver, pancreas, fat, skin and skeletal muscle.
The different types of adult stem cells include multipotent adult progenitor cells,
oligodendrocyte progenitor cells neural stem cells, glial progenitor.
2.2. Major sources of adult stem cells
i. Bone marrow: Anterior or posterior superior iliac crest is the preferred site for the
bone marrow aspiration. If bone marrow cannot be obtained from the iliac crest due
to positioning difficulties or obesity, sternum may be used in adults. However,
aspiration from sternum poses a great risk of complication. [19]
Bone marrow is a proficient source of autologous cells with distinct regenerative properties,
which can be quickly harvested and are thus applicable for both chronic and acute diseases.
Cells isolated from the bone marrow not only differentiate into blood cells but also into neural
tissues. [20] The mononuclear cell fraction derived from the bone marrow is a heterogeneous
population containing differentially matured B-cells, T-cells and monocytes, as well as rare
progenitor cells such as hematopoietic stem cells (HSC), mesenchymal stromal cells (MSC),
endothelial progenitor cells (EPC) and very small embryonic-like cells (VSEL). The hemato‐
poietic stem cells (HSCs) are the blood cells which give rise to the myeloid and lymphoid
lineages. HSCs also have a potential to transdifferentiate into various nonhematopoietic cell
lineages especially neural lineage. [21] [Figure1] Bone marrow mesenchymal stem cells
(BMMSCs) give rise to mesodermal lineage cells such as osteoblasts, chondrocytes, adipocytes,
and muscle cells along with neuroectodermal cells. [22] BMMSCs express a unique surface
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molecule profile, including expression of CD13, CD29, CD44, CD49e, CD73, CD90, CD105,
CD146, CD166, CD271, STRO-1, Octamer-4 (Oct4), and stage-specific embryonic antigen-4
(SSEA4). It is generally believed that BMMSCs are negative for hematopoietic cell markers
such as CD14, CD34, c-kit, SCA1. [23]
It has been observed that use of cell mixture is more efficacious than individual sub fractionated
cells of the bone marrow. They promote angiogenesis, mediate vascular repair, and express
several cytoprotective growth factors and cytokines. These cells are also safe and due to its
easy availability they are most preferred for cellular therapy. These cells are used for the
treatment of various neurological disorders such as cerebral palsy, stroke, Parkinson’s, Spinal
cord injury, etc. along with diabetes, orthopedic conditions, cancers and wound healing. [24,25]
In brain injury, stem cells induce neuroprotection and neural repair by inflammatory sup‐
pression, causing tissue reconstruction of completely or partially damaged cells and prevent
cell death. [26] On administration, these cells migrate to the injured tissue and initiate host
repair and recovery through direct and indirect cell-cell signaling. [27]The safety of use of bone
marrow derived cells has been well established as they have an autologous origin and do not
result in tumor formation.
Figure 1. Bone marrow stem cells
ii. Adipose tissue: Adipose tissue derived stem cells (ASCs) are multipotent cells, found
abundantly in fat tissue. They can differentiate into several lineages, including
Stem Cell Therapy for Cerebral Palsy – A Novel Option
http://dx.doi.org/10.5772/57152
221
adipose cells, chondrocytes, osteoblasts, neuronal cells, endothelial cells, and
cardiomyocytes. These cells are obtained either through liposuction or lipectomy.
Mesenchymal stem cells make up the majority of the adipose derived stem cells. [28]
Due to their plasticity, they are a preferred alternative to the BMSCs. [29] One of the
major disadvantages of adipose derived stem cell is the isolating procedure. There‐
fore, a professional technician is required for cell isolation. In experimental cerebral
palsy models, infusion of adipose derived stem cells has shown to improve physical
activities and cognitive deficits. They have the ability to replace damaged oligoden‐
drocytes and neurons without forming glial scars.[30]
iii. Dental pulp: A population of stem cells has been isolated from the human dental
pulp known as dental pulp stem cells (DPSCs). They have an ability to regenerate a
dentin-pulp-like tissue. [31] DPSCs are a heterogeneous population of cells as they
are composed of both mesenchymal and ectodermic cells. These cells are readily
obtained from routine dental procedures such as removal of impacted third molars,
deciduous teeth and have been shown to possess properties similar to neural stem
cells and mesenchymal stem cells. [32] Under appropriate conditions, these cells also
undergo neuronal differentiation. [33] One of the disadvantages of DPSCs is that it
takes longer to culture mesenchymal stem cells from teeth active tissue. Also, it is
difficult to harvest a large quantity of stem cells from teeth.
iv. Menstrual Blood stem cells: Recently, stem cells have been identified from the
endometrial tissue. The endometrial lining of the uterus has tremendous capacity of
regeneration. The menstrual blood consists of a heterogeneous population of cells.
However, isolation of these cells is a very invasive procedure. [34] Their potential in
CP is not studied.
v. Peripheral blood stem cells: Peripheral blood consists of circulating stem cells
capable of restoring hematopoiesis. Hematopoietic stem cells obtained from PB by
leukapheresis have been used for transplantation as an alternative to bone marrow-
derived stem cells (BM-stem cells). The haemopoietic “potential” of PBSCs is
equivalent to that of BM- stem cells [35] Their use in CP is not well established.
2.3. Various routes of administration of stem cells for cerebral palsy
The appropriate route of cell administration is essential prerequisite for the success of cellular
therapy. For the treatment of cerebral palsy, cells are injected via various routes such as
intrathecal, intravenous and intracerebral.
i. Intrathecal administration: Intrathecal administration of cells involves delivery of
cells via lumbar puncture. It is a minimally invasive procedure as compared to other
routes of administration. This mode of injection allows efficient delivery of cells and
the possibility of migration of cells to the tissues other than the damaged ones is
avoided. [36]
This procedure needs to be done under aseptic condition to avoid any sort of infections. In
case of cerebral palsy, it is considered to be the safe, feasible and efficacious route of admin‐
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istration. In cerebral palsy, studies have shown that this route of administration results in
positive functional outcomes. [37]
ii. Intravenous administration: Intravenous system of delivery of cells has been widely
used in cellular therapy due to its broad bio distribution and easy access. It is one of
the most minimally invasive and safe modes of administration. Studies have shown
that on administering cells intravenously, few cells reach the damaged site while a
majority of cells get trapped in the lungs. Pulmonary passage could be one of the
major hindrances for intravenous administration of stem cells. Hence, for effective
result of intravenous stem cell transplantation, it is necessary to increase the number
of cells injected. [38]
iii. Intracerebral administration: In cerebral palsy, intracerebral transplantation of stem
cells is carried out by injecting cells in the subventricular zone. This leads to migration
of cells to the areas of ischemia but the outcome is not as remarkable as compared to
the other minimally invasive procedures. Additionally, in CP the injury of the brain
is diffused and a local injection could be focused on a particular area which might
not be as effective. Intracerebral injection also increases the risk of bleeding and neural
tissue injury. [39] Since, it is yet to establish cellular therapy as a cure, an invasive
transplantation is not recommended due to the risks involved. Hence, a safer route
of administration should be used.
2.4. Mechanism of action of stem cells in cerebral palsy
To understand the mechanism of action of stem cells in the treatment of cerebral palsy, it is
important to understand the empirical neuropathophysiology. In spite of the vast and varied
etiology; underlying cellular mechanisms, that cause the morbidity or mortality associated
with cerebral palsy, are tissue damage caused by hypoxia and ischemia. The clinical manifes‐
tations of this cellular damage, depends on a range of factors including the time of insult, the
severity of insult and cause of the insult. Brain tissue is heterogeneous and responds differently
to hypoxia and ischemia. Therefore, a certain type of brain tissue is implicated to cause cerebral
palsy. Recent preclinical, immunohistochemical and imaging evidence suggests periventric‐
ular white matter injury (PWMI), particularly damage to oligodendrocytes (OLs) as a primary
cause of cerebral palsy [40,41,42]. PWMI is a spectrum ranging from cystic focal necrotic
lesions, periventricular leuckomalacia (PVL) to specific cortical scarring in the deep regions of
sulci, Ulegyria to diffuse myelination disturbances. Oligodendrocyte progenitors are abun‐
dantly present in the subventricular and periventricualr zones, therefore damage to these cells
is seen as PVL in neuroimaging investigations. The extent of the damage to the white matter
and its consequences are dependent on the developmental stage at which the damage occurred,
brain vascularization and the type of tissue[43].
Vascularization of the brain begins as early as 28th day of gestation with the formation of carotid
arteries, followed by the large arteries, their branches, communicating arteries, long penetrat‐
ing arteries and ends with the formation of short penetrating arteries in the post term period.
Damage at pre term leads to focal cystic necrosis in the vascular end zones of the long
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penetrating arteries causing PVL, damage at term leads to tissue injury at the border zones of
the long and short penetrating arteries giving rise to Ulegyria and damage at post term leads
to diffuse myelination disturbances caused at the vascular end zones of short penetrating
arteries [44]. Subsequently most vulnerable cells, precursors of Oligodendrocytes (OLs),
undergo necrosis through apoptosis. This leads to myelination disturbances. Oligodendro‐
cytes evolve through an established lineage of OL progenitors to pre OLs to immature OLs to
mature OLs. [Figure 2] Hypoxic ischemia as observed in cerebral palsy leads to death of pre
OLs and subsequent deficiency of mature OLs and myelination. Other cell types and mecha‐
nisms that contribute to pathophysiology of CP are axonal damage and microglial activation
[45]. Following this primary insult to the nervous tissue, activation of glial cells leads to
secretion of various chemical mediators of tissue necrosis in the neural microenvironment,
leading to secondary white matter injury. These mediators are Reactive oxygen and nitrogen
species, glutamates, adenosine and inflammatory cytokines like Tumor necrosis factor alpha
(TNF-α), interferon gamma (INF-γ), Interleukin -1 beta (IL-1β) and superoxide radicals [46].
Cellular therapy regulates all of the above cellular mechanisms. Neuroplasticity of the brain
is  maximal  during  childhood.  Hence,  stem cell  intervention  is  more  successful  in  these
children as the integration of new cells in the brain to carry out the repair process is more
effective [47].  Stem cell  possess  the capacity  to  home onto the injured sites  of  brain,  as
guided  by  chemo  attractant  pathway  [48].  The  effects  of  cellular  therapy  are  twofold,
enhancing the brain tissue repair caused by various paracrine mechanisms and regenera‐
tion of neural tissue.  Stem cells help in modifying the microglial  response by exhibiting
immunomodulatory,  neurotrophic  properties  and  enhance  axonal  sprouting.  Various
neurotrophic  factors  secreted  by  the  stem  cells  are  connective  tissue  growth  factor,
fibroblast  growth  factor  2  and  7  that  are  responsible  for  cell  proliferation,  interleukins
responsible for cytoprotection [49,50,51]. Stem cell therapy restores lost myelin by replac‐
ing  dead cells  with  new oligodendrocytes  and their  progenitors.  Indirectly,  it  may also
support their survival by introducing other cell types able to restore missing enzymes to
an otherwise deficient environment [47]. Stem cell therapy also has an anti-inflammatory
effect on the neural microenvironment as they reduce the levels of TNF-α,IL-1β, IL-1α, IL-6
and increased levels of IL-10 [52]; therefore, enhancing the endogenous brain repair. Stem
cells  also  secret  various  growth  factors  like  vascular  endothelial  growth  factor  (VEGF),
fibroblast growth factor (FGF), brain fibroblast growth factor (bFGF). These growth factors
initiate neoangiogenesis and induce secretion of hormones like erythropoietin. The cascade
Figure 2. Phases of Oligodendrocyte development
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events triggered due to these lead to formation of new vessels as well increased bold flow.
Improved blood circulation of the brain thus helps retrieving the lost tissue functions [50].
3. Published literature
Several preclinical experiments on animal models of cerebral palsy have been carried out to
demonstrate the potential of cell transplantation to minimize damage and promote recovery.
However, limited clinical trials have been initiated to study the effect cell therapy in humans.
Human umbilical cord blood cells (hUCBCs) have been explored to a great extent in cerebral
palsy. hUCBCs have been administered in rat models of neonatal hypoxia/ ischemia. They
protect the mature neurons in the neocortex from injury, bring about near-normalization of
brain damage in the subventricular zone (SVZ) leading to significant improvement in behav‐
ioral functions. The long lasting effect of these cells is due to the paracrine effects of hUCBCs
which stimulate recovery in the injured brain and protect against further brain damage. [53]
On transplantation, hUCBCs have shown to ameliorate neurological and motor deficits in CP
model by reducing the levels of pro-inflammatory cytokines (Interleukin-1α (IL-1α), Interleu‐
kin-1β (IL-1β), and Tumor necrosis factor α (TNFα) ) [54,55]
They also alleviate spastic paresis in neonatal rat models resulting in normal walking [56]
Studies have also shown that these cells promote neural stem cell proliferation via Sonic
hedgehog (Shh) signaling pathway improving the brain damage. [57] Human umbilical cord
blood (hUCB) cells have also shown to reduce sensorimotor deficits after hypoxic ischemic
brain injury in neonatal rats. The dimensions of cortical maps and receptive fields, which are
significantly altered after injury, are largely restored. Additionally, the lesion induced hyper-
excitability is no longer observed in treated animals compared to control animals. The results
demonstrate that hUCB cells reinstall the way central neurons process information by
normalizing inhibitory and excitatory processes. [58] it is also observed that these cells exhibit
a neuroprotective effect in the striatum, and decrease the number of activated microglial cells
in the cerebral cortex of treated animals, further resulting in better functional recovery. [59]
Tanaka et al, observed that CD133+ cells derived from hUCBCs reduce the cortical damage
and also promote axonal growth in neonatal rat organ co-cultures exposed to hypoxia. [60]
Various preclinical studies have shown that transplantation of stem cells in the CP models lead
to survival, homing and differentiation of these cells into neurons, oligodendrocytes, astro‐
cytes etc.
Park et al reported clonal neural stem cells (NSCs) when transplanted into brains of postnatal
hypoxic-ischemic (HI) injury mice, home preferentially to and integrate extensively within the
ischemic areas. They differentiate into neurons and oligodendrocytes, the cell types damaged
due to HI. [61] A chinese study, wherein neural stem cells derived from human fetal brain
(hNSCs) were transplanted into cerebral ventricle of HI injury neonatal rat, too demonstrated
the survival, migration and differentiation capacity of these cells in rat brain. [62] Similarly,
Zheng et al showed that Multipotent astrocytic stem cells (MASCs) from mice transplanted
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into a rat model of hypoxia-ischemia (HI) survive, migrate and differentiate into neurons and
astrocytes. [63] In their study, Titomanlio et al implanted neurosphere-derived precursors in
neonatal mouse model of cerebral palsy induced by excitotoxicity. They observed that cells
migrated to the lesion site, remained undifferentiated at day 10, and differentiated into
oligodendrocyte and neurons at day 42. Although grafted cells finally die there few weeks
later, this procedure triggered a reduction in lesion size and an improvement in memory
performance compared with untreated animals. [64] Chen et al, transplanted magnetically
labeled mesenchymal stem cells in a model of perinatal brain injury. They found that these
cells migrate to lesion sites and proliferate. They are neuroprotective and indirectly contribute
to brain repair. [65]
Yasuhara et al, investigated the efficacy of intrahippocampal transplantation of bone marrow
derived multipotent progenitor cells (MPCs) in HI injury. They found that transplanted MPCs
ameliorated motor deficits associated with HI injury. [66] Webber et al in their study high‐
lighted the protective effects of oligodendrocyte precursor cell transplantation in neonatal
inflammation-induced rat model of periventricular leukomalacia. [67]
All the above preclinical studies have been carried out in animal models of acute hypoxic
injury, hence showing significant results. But, similar results are difficult to replicate in human
cases since the intervention always, cannot be carried out immediately post injury. Thus, more
studies should be carried out in chronic injury models. Based on this observation, it can also
be concluded that earlier the intervention, better is the outcome.
Below are few of the published studies carried out in human cases of cerebral palsy.
Luan et al carried out a study on 45 patients diagnosed with severe CP. They underwent
transplantation of neural progenitor cell (NPC) derived from aborted fetal tissue. After 1 year,
the developmental level in gross motor, fine motor, and cognition of the treatment group was
significantly higher compared to the control group. These results suggested that NPC trans‐
plantation is a safe and effective therapeutic method for treating children with severe CP. [68]
Chen et al, injected neural stem cell-like (NSC-like) cells derived from autologous marrow
mesenchymal stem cells in 30 cases of cerebral palsy. On follow up, they observed an increase
in the GMFM scores and language quotients compared to the control group. No adverse events
were recorded indicating that NSC-like cells are safe and effective for the treatment of motor
deficits related to cerebral palsy. [69] Mink et al carried out a double blind, randomized,
controlled trial in which they administered allogeneic umbilical cord blood cells potentiated
with recombinant human erythropoietin (rhEPO) in CP patients. They observed improvement
in motor and cognitive dysfunction in children with CP, accompanied by structural and
metabolic changes in the brain. [70]
Papadopoulos et al administered autologous umbilical cord blood cells in 2 children diagnosed
with spastic diplegic CP. They found that this therapy was safe, feasible and led to functional
improvements in children which was seen by the change in GMFCS. [71]
Li  et  al,  transplanted autologous bone marrow mesenchymal cells  in an 11 year old CP
case with visual impairment. On six month follow up, he could walk better and his vision
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had  improved  significantly.  These  findings  were  supported  by  the  electrophysiological
examinations. [72]
Jensen et al recently published a study wherein a 2 ½ year old boy received autologous
umbilical cord blood mononuclear cells intravenously. At 2-months follow-up the boy's motor
control improved, spastic paresis was largely reduced, and eyesight was recovered, as did the
EEG. He smiled when played with, was able to sit and to speak simple words. At 40 months,
independent eating, walking in gait trainer, crawling, and moving from prone position to free
sitting were possible, and there was significantly improved receptive and expressive speech
competence (four-word sentences, 200 words). This suggested that autologous cord blood
transplantation could be a treatment alternative for cerebral palsy. [73]
Wang et al reported a case of a 5-year old girl with CP who underwent umbilical cord
mesenchymal stem cells (MSCs) transplantation. She was treated with multiple times of
intravenous and intrathecal administration of MSCs derived from her young sister and was
followed up for 28 months. The gross motor dysfunction was improved. Immunity was
enhanced, physical strength improved along with speech and comprehension. [74]
Purandare et al, reported a case of cerebral palsy who was administered with autologous bone
marrow mononuclear cells. On follow up, they recorded a significant improvement in motor,
sensory, cognitive, and speech. Bowel and bladder control was also achieved. On the GMFCS-
E&R level, the patient was promoted from grade III to I. Hence, concluding that intrathecal
infusion of autologous BMMNCs is feasible, effective, and safe in CP patients. [75]
In our previously published cases of cerebral palsy, one was with comorbid intellectual
disability [76] while the other one was without any comorbidity. [77] These cases were
administered with autologous bone marrow mononuclear cells intrathecally. Six months after
the treatment, both cases showed significant functional outcomes which was supported by
improvement in PET CT scan.
3.1. Ongoing trials
Currently, there are five clinical trials on stem cell therapy for cerebral palsy registered in
clinicaltrials.gov. [http://clinicaltrials.gov/]
2 studies are from India studying the safety and efficacy of bone marrow MNCs in cerebral
palsy in children below 15 years. One of the studies is a combination of phase 1 and phase 2
while the other is a combination of phase 2 and phase 3.
2 studies are from Iran, one evaluating the side effects of bone marrow derived CD133 cells
transplantation in cerebral palsy patients and the other studying the safety of multiple
intrathecal injections of bone marrow derived CD133 cells.
A study from USA is based on evaluating the safety and effectiveness of a single, autologous,
cord blood stem cell infusion for the treatment of cerebral palsy in children. It is a randomized,
controlled, blind, crossover study
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4. Administration of autologous bone marrow derived mononuclear cells
in children with cerebral palsy.
Sharma et al, carried out a study on 71 children, wherein they administered 20 cases of cerebral
palsy with autologous bone marrow mononuclear cells, intrathecally. [78] These cases
included dystonic and spastic CP. Symptoms commonly observed in them were delayed
milestones, spasticity, motor impairment, ambulation deficits, cognitive impairment, swal‐
lowing and speech problems etc.
Autologous bone marrow MNCs were selected as they are easily obtainable, safe and do not
involve any ethical issues. As discussed earlier, intrathecal route of administration is a
minimally invasive, safe and an effective procedure as compared to other routes. Studies have
also proved that a mixture of cells exhibits more benefits as compared to a single sub fraction
of cells. [79] Hence, we chose to carry out intrathecal autologous BMMNC transplantation.
The patients were administered Granulocyte Colony Stimulating Factor (GCSF), 48 hours and
24 hours before the harvest and transplantation of BMMNC. On the day of the transplantation,
bone marrow was aspirated under general anesthesia in the operation theatre with aseptic
precautions. Approximately, 100 ml of bone marrow (varying between 80 ml and 100 ml, based
on the age and body weight) was aspirated from the region of anterior superior iliac spine
using the bone marrow aspiration needle and collected in the heparinized tubes.
The aspirate was then transferred to the laboratory where the mononuclear cells were
separated by the density gradient method. CD34+ counting was done by Fluorescence
activated cell sorting (FACS). The MNCs were checked for viability (Average viability count
was found to be 97%).
The separated autologous BMMNCs were immediately injected on the same day, intrathecally
using an 18G Touhy needle and epidural catheter at the level between fourth and fifth lumbar
vertebrae. The average numbers of cells injected were 8.19 x 107. Simultaneously 20mg/kg body
weight methyl prednisolone in 500 ml Ringer Lactate was given intravenously to enhance
survival of the injected cells. Patient was monitored for any adverse events.
On mean follow up of 15 months ± 1 month post stem cell administration, improvement was
observed in 85% cases. [Figure 3] Significant improvement was observed in spasticity, neck
holding, drooling of saliva, muscle strength in upper and lower limbs, sitting and standing
balance, gross and fine motor activities, speech, swallowing, ambulation, and cognition. There
was also a reduction in dystonic movements. No major adverse events were recorded. Some
minor side effects such as headache, nausea and vomiting were experienced by few children
who were self-limiting (resolved within a week) and treated with medications. The improve‐
ments in these patients sustained even after the follow up period of the study. None of them
showed any deterioration on the GMFCS [78]
We are also currently conducting a clinical study to assess the efficacy of autologous BMMNC
in 64 patients with CP. These patients are being treated with a combination of cell therapy and
rehabilitation. The unpublished data analysis have shown preliminary results as improvement
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in oromotor skills, speech, neck holding, sitting, standing and walking balance and significant
reduction in muscular tone and dystonic movements. These changes were observed in all types
of cerebral palsy over 6 months with varied follow up periods. [Figure 4,5,6]
Figure 3. Graph demonstrating overall improvements in CP patients after stem cell therapy.
Percentage improvement noted in patients of diplegic cerebral palsy was as follows. Oromotor
skills (75%), speech (64%), neck holding (100%),Sitting balance (67%), standing balance(67%),
walking balance (67%), ambulation (30%), leg movements (54%), overhead movements (38%),
distal hand movements (69%), upper limb spasticity (38%), Lower limb spasticity (38%), trunk
muscle tone (36%), trunk dissociation (30%)
Percentage improvement noted in patients of quadriplegic cerebral palsy was as follows.
Oromotor skills (58%), speech (40%), neck holding (94%),Sitting balance (48%), standing
balance(27%), walking balance (21%), ambulation (13%), involuntary movements (25%), upper
limb spasticity (51%), Lower limb spasticity (50%), trunk muscle tone (36%)
Percentage improvement noted in patients with other types of cerebral palsy was as follows.
Oromotor skills (55%), speech (55%), neck holding (40%),Sitting balance (45%), standing
balance(50%), walking balance (27%), involuntary movements (9%), upper limb spasticity
(22%), lower limb spasticity (14%), dystonia of upper limbs (50%), dystonia of lower limbs
(100%), dystonia of the trunk (50%)
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Figure 4. Graph demonstrating improvements in Diplegic CP patients after stem cell therapy
Figure 5. Graph demonstrating improvements in Quadriplegic CP patients after stem cell therapy
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Figure 6. Graph demonstrating improvements in other types of CP patients after stem cell therapy
5. Objective imaging evidence
Various clinical outcome measures have been devised to measure changes in sensory, motor,
cognitive, perceptual and Behaviour functions in CP. [80] It is however important to under‐
stand the underlying mechanisms behind these changes.
MRI scans not only help reveal the underlying pathology of CP, but it also correlates with the
clinical findings. [81] It has been observed that, clinical trials using MRI as a primary outcome
measure failed to fully identify the effects of the therapy on clinical measures. [82] MRI shows
the structural malformations and grey and white matter lesions, these are only suggestive of
underlying tissue mechanisms; but MRI is not sensitive to measure the changes at cellular
level. Principle mechanisms underlying the benefits of cellular therapy are the changes brought
about in the microenvironment of cells reducing cell necrosis, ischemia and hypoxia. These
changes therefore cannot be measured on a plane MRI and hence it is not a sensitive tool to
monitor the effects of stem cell therapy. Functional neuroimaging on the other hand may be
an appropriate option to monitor the finer changes at cellular level.
The basic principle underlying the functional neuroimaging of the brain is that the cerebral
blood flow and metabolism is associated with neuronal activity. [83] Stem cell therapy aims
to modulate neuronal tissue function in the patients of cerebral palsy, through various
paracrine mechanisms. Measurement of the tissue function is therefore a preferred outcome
measure to monitor the effects of cellular therapy.
Positron Emission Tomography – Computed Tomography (PET – CT) is one of the techniques
of functional neuroimaging that measures the metabolism of the nervous tissue in terms of
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Fleuro-deoxy glucose (FDG) uptake. FDG is a radioactive glucose analogue that undergoes
glycolysis in the same manner as that of glucose. Once it has been metabolized to FDG – 6 –
Phosphate it cannot be further metabolized and is trapped inside the cell due to the imper‐
meability of the cell membrane for this molecule. With increased glycolysis higher concentra‐
tion of FDG-6-phosphate is observed. Photons emitted by this radioactive isotope are then
measured to identify concentration of FDG in the nervous tissue [84]. This is expressed as a
ratio of the actual uptake and the calculated presumed uptake of FDG, standard uptake value
[85]. Because of its ability to measure the finer changes in tissue metabolism, FDG PET-CT
holds a great potential as a monitoring tool. [86,87]
PET-CT scan is performed following a standard protocol. Various guidelines are available for
appropriate standardization, image acquisition and interpretation during PET-CT scanning.
Dosage of the radioactive dye is calculated based on the age and weight of the patient.
Calculated units are then administered systemically 30 minutes before scanning. [88].
FDG, chemically expressed as 18F-FDG is radionuclide and therefore special safety concerns
with its use need to be address. The primary safety concern is exposure to radiation. Incidence
of developing any side effect is negligible with the use of 18F-FDG PET-CT. The half-life of
18F-FDG is 109.8 minutes and is excreted via urine. The tissue metabolism of 18F-FDG is the
same in adult and children and the dose administered in children is “as low as reasonably
achievable”. Various adjustments with regards to scanning technology and measurement
period are made to enhance the quality of the image with the administered dose [89]. PET-CT
is sensitive to measure the cellular changes and it is a standardized imaging modality which
makes it a good monitoring tool to assess the effects of cellular therapy.
In our previous case studies involving cerebral palsy patients treated with autologous bone
marrow derived mononuclear cells (BMMNCs), the clinical outcome was correlated with
changes in the PET scan. In one case of a 20 year old CP patient with co morbid intellectual
disability, a repeat PET-CT scan showed significant increase in the FDG uptake in various
affected areas of the brain, which correlated with the clinical improvement in social behavior,
balance and motor control. However the MRI remained unchanged (76).
In another case of a 2 year old child with cerebral palsy, we observed similar correlation of
clinical improvement with the PET-CT changes in metabolism. (77) Six months following
cellular therapy she developed good neck control along with improvement in balance and
speech. These clinical changes were synonymous with the increased FDG uptake in the
bilateral mesial temporal structures, right basal ganglia, frontal, parietal, temporal and
occipital lobes.
Functional MRI is also one of the emerging techniques to study the functional outcome of the
intervention. The technique of fMRI is based on Blood oxygenation level dependent (BOLD)
contrast between rest and activated states of human brain. (90) Activation of neuronal tissue
leads to increased metabolism and increased oxygen demands that have a twofold effect of
greater oxygen extraction and increased cerebral blood flow; both of which result in higher
BOLD signals than that of resting tissue. In ischemic tissues the blood flow–metabolism couple
is impaired. Stem cells enhance angiogenesis, increasing the cerebral blood flow. Hence, fMRI
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may be effectively used to monitor the therapeutic outcome of stem cell therapy and should
be studied further. (91)
6. Role of rehabilitation in combination with stem cell therapy
For a long time, rehabilitation has been the standard approach for cerebral palsy. The goal of
rehabilitation in cerebral palsy is to develop coordination, build strength, improve balance,
maintain flexibility, optimize physical functions, manage spasticity and maximize independ‐
ence. Rehabilitation is multidisciplinary. Various therapeutic regimens aim to enhance
particular clinical, functional and psychosocial consequences of CP. Physiotherapy, makes use
physical modalities to muscle spasticity, increase flexibility, balance and co-ordination, build
strength and enhance function. Physiotherapists also prescribe different assistive devices to
gain higher functionality. Multiple medical and surgical regimens are also instituted to deal
with these physical impairments. Botox injections are most commonly used to reduce spasticity
of the muscles, but the effects are short lived. A variety of surgical techniques are utilized to
correct deformities.
Occupational therapy is focused at therapeutic regimens to improve cognitive abilities of the
child and increase participation in activities of daily and social living. Children with CP most
often present with poor oromotor control and speech disorders, speech therapy aims at
correcting these impairments. Psychiatric and psychological intervention is aimed at patient
and caregiver wellbeing. It helps to improve the quality of life by addressing co-morbid
psychological disturbances and cognitive impairments.
All of the rehabilitative modalities face the fundamental limitation of inability to repair the
damage to the nervous tissue. Some studies have defined minor improvements in motor and
social skills. Wright and Nicholson and Sommerfeld et al have demonstrated that physical
therapy alone does not show a consistent benefit in cerebral palsy. [92]
However, rehabilitation in combination with stem cell therapy may augment its benefits.
Exercise helps in enhancing the cell proliferation and neurogenesis. [93] Increased mobilization
of hematopoietic stem cells and erythropoieticprogrnitor cells (EPCs) to peripheral blood is
observed post exercise. It also increases angiogenesis and oxygen supply to the brain thereby
improving the cognitive function. [94,95,96]. Regular exercise induces suppression of pro-
inflammatory cytokines and up regulation of anti-inflammatory cytokines in various tissues
of the body including brain. [97,98,99] One of the key mechanisms for homing of bone marrow
mononuclear stem cells is the chemokine stromal derived factor -1 / CXCR4+ receptor pathway,
exercise has also been found to up regulate expression of CXCR4+ receptors is ischemic tissue
ensuring enhanced homing of stem cells. In addition, mobilization of stem cells, enhanced
homing, improved angiogenesis exercise also exerts immunomodulatory effects. [97] Benefits
of regular exercise resonate with the cellular mechanisms of stem cell therapy and therefore it
augments the therapeutic potential of stem cell therapy. Exercise and rehabilitation has a
synergistic effect for the benefits of cell transplantation. [100]
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7. Future direction
Stem cell therapy for cerebral palsy still remains in its infant stage. Although cellular therapy
for cerebral palsy has moved from the preclinical studies to bedside therapy; evidence remains
inconclusive regarding multitude of variables. These variables are pertaining to cerebral palsy
and cellular therapy.
Cerebral palsy is a heterogeneous group of disorders. This inherently reduces the generaliza‐
bility of the findings. Pre-clinical models of effects of cellular therapy in cerebral palsy are far
from the ideal state and show benefits only in acute injury. Majority of the human application
of stem cells in cerebral palsy is for individuals who already have established pathology, hence
at a chronic stage. Animal models of chronic injury are therefore required to study the efficacy
and mechanism of action of stem cells. The individuals suffering from cerebral palsy are from
various age groups, and present with varied kinds and severities of clinical manifestations;
there is only a limited evidence about which of these groups will benefit the most from cellular
therapy.
Only preliminary evidence using basic research methodologies is available for the effects of
cellular therapy in humans. Various factors limit the methodological robustness of the current
trials. There are limited controlled trials in humans with cerebral palsy. We require more
double blind, randomized, multicenter controlled clinical trials to prove the safety and
feasibility of stem cells. The evidence available is heterogeneous in methodology, patient
population, outcome measures and cellular therapy provided. Stem cells provide their
beneficial effects through numerous mechanisms; it is difficult to underpin the exact mecha‐
nism of action of stem cells. Types, sources and numbers of cells administered, frequency of
transplantation, time of transplantation are concerns which require attention imperatively. It
is important to not only conduct more trials but also to standardize research protocols to allow
comparison. Comparative studies will help in establishing the most effective cell based therapy
for cerebral palsy.
Apart from these issues, development and validation of outcome measures to obtain evidence
of the efficacy of intervention is very important. Different scales, monitoring tools need to be
standardized. Modalities should be developed to study the effect of cell transplantation at a
cellular level. Outcomes that can successfully assess these cellular changes are measuring the
serum, plasma and cerebrospinal fluid biomarkers, which are invasive. Less invasive modal‐
ities would be functional imaging techniques. PET-CT scan has been used as an outcome to
assess the effects of cellular therapy however it is required to further explore its various
components in depth. fMRI also provides insights regarding the changes at cellular level
however there is no evidence of its use in monitoring the changes post cellular therapy. It is
therefore necessary to explore how functional imaging can provide us a better understanding
of the cellular mechanisms.
8. Conclusion
Stem cell therapy has been extensively studied but still needs to be standardized before it
becomes a definitive treatment modality. Autologous BMMNCs are safe and feasible option
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but their effectiveness needs more clinical trials. Other types of stem cells need to establish
safety and efficacy. Though not a cure, stem cell therapy has emerged as a novel therapeutic
option to improve the quality of life.
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